Share 'FDA Approves First Drug for Parkinson's Dementia'
(PSYCHIATRIC TIMES) - ROCKVILLE, Md., June 28 — The FDA has given Exelon (rivastigmine), already approved for treatment of mild-to-moderate Alzheimer's dementia, the added indication of mild-to-moderate Parkinson's dementia.
Exelon, marketed by Novartis, became the first agent approved for the Parkinson's condition.
Steven Galson, M.D., director of the FDA's Center for Drug Evaluation and Resea…
You can share this blog post in two ways…
Share this link:
Send it with your computer's email program: Email this